publication date: Jun. 8, 2018
Issue 23 - Jun. 8, 2018
  • Big takeaway from ASCO: 70 percent of women with early breast cancer don’t benefit from adjuvant chemotherapy

    An NCI-sponsored trial showed that up to 70 percent of women with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer would not benefit from chemotherapy.

  • Conversation with The Cancer Letter

    Abrams: Only about 20-30 percent of the group might benefit from chemotherapy

    The practice-changing TAILORx trial was brought to you by publicly funded cancer clinical trials system, pointing to its continuing relevance, said Jeff Abrams, NCI acting director for clinical research and associate director of the Cancer Therapy Evaluation Program.

  • Sharpless: NCI adds $10 million for NCTN and NCORP trials

    NCI is providing an additional $10 million to support trials run with the National Clinical Trials Network and the NCI Community Oncology Research Program, Norman “Ned” Sharpless said in his first appearance as NCI director at the annual meeting of the American Society of Clinical Oncology in Chicago. “NCI’s major efforts with regards to large clinical trials are largely supported through our clinical trials networks like the National Clinical Trials Network,” Sharpless said in his June 2 talk at ASCO. “One of the major challenges for these networks over the past few years, however, has been a rapid increase in the per-patient costs for patients on trials.

  • In Brief

    • J&J Innovation and Boston University form lung cancer research alliance
    • Kochevar to retire from Colorado Cancer Center
  • Funding Opportunities

    Addario, Van Auken foundations announce 2018 Young Innovators Team Award

    The Bonnie J. Addario Lung Cancer Foundation, in collaboration with the Van Auken Private Foundation, announced the 2018 Young Innovators Team Award to fund and support teams of young investigators conducting innovative research with a potential of delivering meaningful and measurable results in the field of lung cancer.

  • TCCL Logo

  • Trials and Tribulations

    Searching for Breast Cancer’s “Extreme Survivors” 

    I remember the day I met Margaret “Peg” Geisler, who has now been living with breast cancer for 40 years, and with metastatic disease for 36 of those years.

  • Clinical Roundup

    • New treatment combination improves outcomes for some patients with colorectal cancer
    • Exact Sciences, Mayo Clinic identify blood-based DNA biomarkers to diagnose hepatocellular carcinoma
    • Opdivo demonstrates superior RFS vs. Yervoy for patients with resected stage III or IV melanoma
    • Opdivo plus Yervoy provide QOL improvements in RCC

Copyright (c) 2018 The Cancer Letter Inc.